Form 4: EXAS Exec Sells Shares Under 10b5-1 Plan

Exact Sciences EVP Brian Baranick sold 2,858 shares of common stock for $70.08 per share under a pre-arranged trading plan.

Summary

• Brian Baranick, Executive Vice President and General Manager of Precision Oncology at Exact Sciences Corp. (EXAS), sold 2,858 shares of the company's common stock.
• The transaction occurred on November 4, 2025, with shares sold at a price of $70.08 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Baranick established on May 13, 2024.
• Following this transaction, Mr. Baranick directly holds 22,368 shares of common stock and indirectly holds an additional 670 shares in a 401(k) Plan, totaling 23,038 shares reported on this Form 4.
• In addition to the reported shares, Mr. Baranick also holds 73,080 vested and unvested options to purchase common stock and restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan indicates a pre-planned, non-discretionary transaction, which mitigates concerns about management's immediate outlook on the company.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not necessarily reactive decision, which can mitigate concerns about insider selling.

Negatives

• An executive selling shares, even under a 10b5-1 plan, could be perceived negatively by some investors, potentially raising questions about management's long-term outlook, though this is often a routine personal financial management activity.

Future Outlook

Not applicable, as this Form 4 filing primarily reports a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide specific insights into broader industry trends or the competitive landscape. Such transactions are common for executives managing personal finances and diversifying holdings.

Stakeholder Impact

• Shareholders: May observe an executive selling shares, but the 10b5-1 plan suggests a routine financial management decision rather than a signal of company distress, thus the direct impact is likely minimal.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned insider sale by an executive under a Rule 10b5-1 plan. It does not provide new fundamental information about Exact Sciences' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should consider this a standard disclosure and rely on broader company fundamentals and market analysis for investment decisions.

Keywords

Exact Sciences, EXAS, Insider Sale, Form 4, Brian Baranick, 10b5-1 Plan, Common Stock, Executive Compensation